ALCJ Crossject Société Anonyme

1.468USD1.338 EUR · EPA-0.15%Mkt Cap: 89.11M USDP/E: —

Crossject Société Anonyme develops needle-free injection systems in France. The company develops ZENEO, needle-free, pre-filled, single-use auto-injector. It offers Midazolam for epileptic seizure; Terbutaline for the tr…

Key Statistics

Company
Market Cap89.11M USD
Enterprise Value96.78M USD
Revenue (TTM)150.26K USD
Gross Profit-10.65M USD
Net Income (TTM)-11.37M USD
Revenue/Share0.0022 USD
Last Price1.468 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees110
CountryFR
SectorHealthcare
IndustryMedical Instruments & Supplies
ISINFR0011716265
Valuation
P/E (Trailing)—
P/E (Forward)2.58
PEG—
EV/EBITDA-6.64
EV/Revenue644.07
P/S593.01
P/B26.80
EPS (TTM)-0.26 USD
EPS (Forward)0.57 USD
52W Range
1.20616% of range2.830
52W High2.830 USD
52W Low1.206 USD
Profitability
Gross Margin0.00%
Oper. Margin-11245.25%
EBITDA Margin0.00%
Profit Margin0.00%
ROE212.74%
ROA-34.07%
ROIC-72.86%
ROCE-56.46%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-6.96M USD
CapEx (TTM)4.94M USD
FCF Margin-5776.48%
FCF Yield-9.74%
Net Debt8.56M USD
Net Debt/EBITDA-0.59
Net Debt/FCF—
Balance Sheet
Debt/Equity-4.61
Current Ratio2.15
Quick Ratio1.64
Book Value/Sh0.05 USD
Cash/Share0.23 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)4.552 USD
Upside (mean)+210.2%
Target Range4.387 USD – 4.716 USD
4.387+210.2% to mean4.716
# Analysts2
Ownership
Shares Out.60.63M
Float44.99M
Insiders19.63%
Institutions0.40%
Technical
SMA 501.436 (+2.2%)
SMA 2001.881 (-22.0%)
Beta0.47
S&P 52W Chg12.00%
Avg Vol (30d)154.93K
Avg Vol (10d)164.97K
Technical Indicators
RSI (14)53.8
MACD0.0113
MACD Signal-0.0002
MACD Hist.+0.0116
BB Upper1.542 USD
BB Middle1.416 USD
BB Lower1.289 USD
BB Width17.85%
ATR (14)0.0711 USD
Vol Ratio (20d)0.38x

About Crossject (EPA: ALCJ)

›

Crossject (EPA: ALCJ) is listed on Euronext Paris, where its shares trade in EUR. It belongs to the Medical Instruments & Supplies industry, part of the Healthcare sector, and reports about 110 employees.

The shares were at 1.338 EUR on 19 November 2026, down 43.3% over 52 weeks. Its 52-week range is 1.100 EUR to 2.580 EUR: the price is 48.1% below the high and 21.6% above the low.

Its market capitalisation is 81.24M EUR.

Crossject reports return on equity of 212.7%.

Its debt exceeds its cash by 7.80M EUR. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health. 2 analysts cover the stock; their mean price target of 4.150 EUR is 210.2% above the current price.